NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression

Stock Information for Neuronetics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Neuronetics Inc.

Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results
Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call
Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.